Vizamyl
Drug
GE HealthCare
Total Payments
$199,582
Transactions
17
Doctors
5
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $104,042 | 14 | 5 |
| 2023 | $95,540 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $172,510 | 7 | 86.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,436 | 4 | 7.7% |
| Consulting Fee | $9,500 | 5 | 4.8% |
| Travel and Lodging | $2,136 | 1 | 1.1% |
Payments by Type
Research
$172,510
7 transactions
General
$27,072
10 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| FLUTE-21-01B: BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers (TRACE-B) | GE HealthCare | $53,390 | 0 |
| VZML-21-03: 18F-flutemetamol PET/CT Imaging of ATTR-Cardiac Amyloidosis (FICA) Study | GE HealthCare | $25,290 | 0 |
| Alzheimers Study | GE HEALTHCARE | $7,250 | 0 |
Top Doctors Receiving Payments for Vizamyl
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Providence, RI | $172,510 | 7 |
| , MD | Diagnostic Radiology | Los Angeles, CA | $15,108 | 3 |
| , MD | Nuclear Imaging & Therapy | Washington, DC | $5,000 | 2 |
| , M.D | Hospitalist | Charlottesville, VA | $2,500 | 1 |
| , MD | Allergy & Immunology | Kailua, HI | $2,464 | 2 |
| , MD | Neurology | Phoenix, AZ | $2,000 | 2 |
Ad
Manufacturing Companies
- GE HEALTHCARE $104,042
- GE HealthCare $95,540
Product Information
- Type Drug
- Total Payments $199,582
- Total Doctors 5
- Transactions 17
About Vizamyl
Vizamyl is a drug associated with $199,582 in payments to 5 healthcare providers, recorded across 17 transactions in the CMS Open Payments database. The primary manufacturer is GE HealthCare.
Payment data is available from 2023 to 2024. In 2024, $104,042 was paid across 14 transactions to 5 doctors.
The most common payment nature for Vizamyl is "Unspecified" ($172,510, 86.4% of total).
Vizamyl is associated with 3 research studies, including "FLUTE-21-01B: BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers (TRACE-B)" ($53,390).